AIM ImmunoTech Inc.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AIM ImmunoTech Inc. is a leading immuno-pharmaceutical company dedicated to the research and development of innovative therapies for a variety of cancers, viral infections, and immune system disorders. The company's flagship investigational drug, Ampligen (rintatolimod), is a synthetic double-stranded RNA molecule operating as a Toll-like Receptor 3 (TLR3) agonist. Ampligen is being explored in multiple clinical trials for various solid tumor cancers, including a primary focus on metastatic pancreatic cancer, where it is being evaluated in combination with other immunotherapies. It is also undergoing assessment for applications in conditions such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID conditions, with positive preliminary data reported in these areas. Ampligen is commercially approved in Argentina for treating severe chronic fatigue syndrome. Beyond Ampligen, the company offers Alferon N Injection, a natural alpha interferon formulation approved for treating refractory genital warts. AIM ImmunoTech actively engages in strategic collaborations with major cancer research centers and has secured patents for Ampligen's use in combination therapies for various cancers and for long-COVID treatments in key markets like Japan and Europe. Headquartered in Ocala, Florida, the company, formerly known as Hemispherx Biopharma, Inc., rebranded to AIM ImmunoTech Inc. in 2019, reflecting its core mission in amplified immunological modulation. The company continues to advance its pipeline with an emphasis on addressing unmet medical needs in oncology and debilitating chronic conditions.
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
Coiled Therapeutics develops improved formulation of experimental cancer drug ahead of trial expansion
Phoenix Copper shares drop on discount equity raise
Greatland Resources ramp-up continued through June 2026
Update on Intention to Move from AIM to Main Market
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
Coiled Therapeutics appoints biotech veteran Craig Tooman to board
AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences
OUST's AIM Partnership Validates Rev8's Commercial Promise
Metals One builds 5.57% stake in newly listed Talon Resources
Cavendish backs CelLBxHealth turnaround with buy rating, 4p target
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
CelLBxHealth guides for 50% revenue growth as partnership pipeline swells
Union Jack Oil 's Crossroads well disappoints with non-commercial result
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area
Optima Health trading 'in line' as it continues to grow UK and Ireland platform